Cincinnati Children's Hospital Medical Center
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1883-01-01
- Employees
- 10K
- Market Cap
- -
Clinical Trials
626
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (468 trials with phase data)• Click on a phase to view related trials
Anticoagulation Adherence Measurement Strategies
- Conditions
- Anticoagulation
- First Posted Date
- 2025-08-19
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 30
- Registration Number
- NCT07129395
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Serial Assessment of Fertility Experiences
- Conditions
- Sickle Cell Anemia
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 250
- Registration Number
- NCT07116772
- Locations
- 🇩🇴
Centro de Obstetricia y Ginecologia, Santo Domingo, Dominican Republic
🇯🇲Caribbean Institute for Health Research, University of West Indies, Kingston, Jamaica
Full Assessment of Clinical Transfusion Support
- Conditions
- Sickle Cell AnemiaBlood TransfusionMalaria Parasitaemia
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 250
- Registration Number
- NCT07094646
- Locations
- 🇺🇬
Jinja Regional Referral Hospital (JRRH), Jinja, Uganda
Comprehensive Assessment of Reactions to Pharmacogenetics in Complex Care Patients
- Conditions
- Pediatric Medical Complexity Based on PMCA Score of 3
- First Posted Date
- 2025-07-11
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 500
- Registration Number
- NCT07060300
- Locations
- 🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
Engaging Mental Health Services for Preschoolers at Risk
- Conditions
- Mental Health DisorderFamily NavigationMinoritized PopulationPreschool Age Children
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 106
- Registration Number
- NCT07054554
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 125
- Next
News
Blue Lake and CyanVac Report Promising Phase 1 Results for Intranasal COVID-19 Vaccine CVXGA
Blue Lake Biotechnology and CyanVac published full Phase 1 data in Science Advances showing their intranasal COVID-19 vaccine candidate CVXGA demonstrated safety and immunogenicity in 72 healthy subjects aged 12-51 years.
First US Nasal COVID-19 Vaccine Shows 67% Infection Reduction in Phase 1 Trial
CyanVac's CVXGA nasal COVID-19 vaccine demonstrated a 67% reduction in infection risk compared to unvaccinated individuals in the first US-based phase 1 clinical trial.
FDA Approves Gamifant as First Treatment for Macrophage Activation Syndrome in Still's Disease
The FDA has approved Gamifant (emapalumab-lzsg) as the first-ever treatment for adults and children with macrophage activation syndrome in Still's disease, marking a significant breakthrough for patients with this life-threatening condition.
NIH Launches Influenza Human Challenge Study to Advance Vaccine Development
The National Institute of Allergy and Infectious Diseases (NIAID) has initiated a clinical trial where healthy adults will be deliberately infected with influenza virus under controlled conditions at four research sites across the US.
FDA Approves First Treatment for Primary Hemophagocytic Lymphohistiocytosis, Marking 24-Year Breakthrough
The FDA has approved emapalumab-lzsg (Gamifant) as the first treatment specifically indicated for primary hemophagocytic lymphohistiocytosis (HLH), an ultra-rare and life-threatening immune disorder.